ENTRY       D11064            Mixture   Drug
NAME        Sitagliptin and ipragliflozin;
            Sujanu (TN)
COMPONENT   (Sitagliptin phosphate [DR:D06645] | Sitagliptin [DR:D08516] | Sitagliptin phosphate [DR:D12294]), (Ipragliflozin [DR:D10196] | Ipragliflozin L-proline [DR:D10200])
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
            Metabolizing enzyme substrate
             DG02924  UGT substrate
              DG03190  UGT2B7 substrate
REMARK      Therapeutic category: 3969
            Product: D11064<JP>
EFFICACY    Antidiabetic
COMMENT     Ipragliflozin is primarily metabolized by UGT2B7.
METABOLISM  Enzyme: UGT2B7 [HSA:7364]
INTERACTION  
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               396  Antidiabetic agents
                3969  Others
                 D11064  Sitagliptin and ipragliflozin
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
                D11064  Sitagliptin and ipragliflozin
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG03190  UGT2B7 substrate
                D11064  Sitagliptin and ipragliflozin
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               D11064  Sitagliptin and ipragliflozin
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D11064
DBLINKS     PubChem: 375581011
///
